Centessa Pharmaceuticals

A new kind of pharmaceutical company delivering asset centricity at scale.

General Information
Company Name
Centessa Pharmaceuticals
Founded Year
2021
Location (Offices)
Founders / Decision Makers
Tia Bush - Chief Quality Officer Saurabh Saha MD PhD - Chief Executive Officer Harris L. Rotman - Senior Vice President, Regulatory Affairs Thomas Templeman - Chief Technology Officer John Crowley - Chief Financial Officer David Chao - Chief Administrative Officer Doris Sanchez - Vice President, Chief of Staff, Global Development
Number of Employees
90
Industries
Biotechnology, Pharmaceutical
Funding Stage
Post Ipo Equity
Social Media

Centessa Pharmaceuticals - Company Profile

Centessa Pharmaceuticals is a clinical-stage pharmaceutical company that operates with a unique approach, focusing on asset centricity at scale. The company's Research & Development innovation engine is dedicated to discovering, developing, and delivering impactful medicines to patients. With a portfolio spanning from discovery-stage to late-stage development, Centessa covers a range of high-value indications in rare diseases and immuno-oncology. The company's headquarters are located in Boston, Massachusetts. Led by a management team with extensive R&D experience, Centessa benefits from direct guidance to rapidly advance candidates from research through all stages of development. Founded in 2021, Centessa operates within the Biotechnology and Pharmaceutical industries. The company recently received a significant $300.00M investment in Post-IPO Debt, on 04 October 2021, from Oberland Capital. With its innovative approach and strong financial backing, Centessa Pharmaceuticals has the potential to make significant strides in the pharmaceutical industry.

Taxonomy: pharmaceuticals, clinical-stage, R&D, innovation, medicine development, rare diseases, immuno-oncology, asset-centric model, biopharmaceutical, Boston, drug development, validated programs, management team, next-generation

Funding Rounds & Investors of Centessa Pharmaceuticals (3)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $100.00M - 23 Apr 2024
Post-IPO Debt $300.00M 1
Oberland Capital, investor in Centessa Pharmaceuticals's Post-IPO Debt round
04 Oct 2021
Series A $250.00M 9
Franklin Templeton Venture Capital, investor in Centessa Pharmaceuticals's Series A round Boxer Capital, investor in Centessa Pharmaceuticals's Series A round T. Rowe Price, investor in Centessa Pharmaceuticals's Series A round Wellington Management, investor in Centessa Pharmaceuticals's Series A round Logos Capital, investor in Centessa Pharmaceuticals's Series A round Vida Ventures, investor in Centessa Pharmaceuticals's Series A round Cormorant Asset Management, investor in Centessa Pharmaceuticals's Series A round Venrock Healthcare Capital Partners, investor in Centessa Pharmaceuticals's Series A round
Biotechnology Value Fund 		16 Feb 2021

Latest News of Centessa Pharmaceuticals

View All

No recent news or press coverage available for Centessa Pharmaceuticals.

Similar Companies to Centessa Pharmaceuticals

View All
Bots 'N Brains - Similar company to Centessa Pharmaceuticals
Bots 'N Brains We work as your Research & Product Development partner to build select Medical Device technologies.
SB Drug Discovery - a Sygnature Discovery business - Similar company to Centessa Pharmaceuticals
SB Drug Discovery - a Sygnature Discovery business The best path to drug discovery
Webdevelop Pro - Similar company to Centessa Pharmaceuticals
Webdevelop Pro The software consulting and development company that can drive a project from an early stage idea to a stable business.
Toragen, Inc. - Similar company to Centessa Pharmaceuticals
Toragen, Inc. Novel small molecule therapeutics targeting oncogenic viruses
Catalyst Biosciences - Similar company to Centessa Pharmaceuticals
Catalyst Biosciences